DementiaHADNCT06483438
Handwriting as an Objective Tool to Support the Identification of People With Alzheimer's Disease
An observational study of Dementia, run by University of Évora at 3 sites in Portugal.
Trial summary
Alzheimer's disease (AD) is the most common of dementia, and has associated cognitive and motor disorders, with consequences on daily activities, including handwriting. Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dementia
- How many people
- 20 participants
- Where
- 3 sitesPortugal
- Study dates
- 2 Dec 2023to 30 Jul 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants will be recruited from Municipal and Community Associations, Senior Universities and Residential Centre for the Elderly
Who may be able to join
- Over 50 years of age
- The inclusion criteria for the dementia group are as follows: patients diagnosed with dementia according to the DSM-5 criteria and cognitive impairment proven in the neuropsychological assessment
- Portuguese native language
- Over 50 years of age
- At least three years of schooling
Who cannot join
- Previous neurological history (e.g. stroke, traumatic brain injury, multiple sclerosis, among others), psychiatric history or other incapacitating illnesses that could interfere with the collection of writing data. (NOTE that neurological disease is accepted in the dementia group, but co-morbidity of previous and actual neurological diseases will be excluded) Cognitively normal group
- Presence of neurological history (e.g., stroke, traumatic brain injury, multiple sclerosis, among others), psychiatric history, or other incapacitating illnesses that could interfere with the collection of writing data.
Trial locations and contacts
3 sites in 1 country.
Portugal3 sites
Espírito Santo Hospital of Évora
Evora, 7000
Casa dos Avós Residence
Ponte de Sôr, 7400
Costa Azul Residence
Sesimbra, 2970
About this study
Official title: Handwriting as an Objective Tool to Support the Identification of People With Alzheimer's Disease: Suitability of an Assessment Protocol
Alzheimer's disease (AD) is the most common of dementia, and has associated cognitive and motor disorders, with consequences on daily activities, including handwriting.
Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations. Changes in this skill are present at different stages of the clinical course of Alzheimer's Disease. The sensorimotor deterioration is observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles) and brain activity rhythms.
Read more
Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations, and changes in this skill are present at different stages of the clinical course of dementia. From a theoretical perspective, because sensorimotor deterioration observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles).
Due to the large number of brain areas related to handwriting performance, brain electrical activity analysis can be an early indicator of brain dysfunction. Although there is a lack of validation across healthy and non-healthy populations Electroencephalogram (EEG) measures have the potential for evaluating cognitive performance.
This research aims to analyze the suitability of the handwriting assessment protocol, which can contribute to a more in-depth knowledge of this subject and potentially support early identification and treatment.
Read the detailed description
The minimum sample size for this pilot study is 75 participants, which is the minimum sample size calculated by G*power (90% power, significance level 0.05) to perform the planned between-group comparisons (ANOVA), correlations (Pearson), and nonlinear analyses. Participants who agree to participate in this study will be asked to provide demographic information, such as age, Portuguese as a native language, education level, motor/physical problems, and medical problems. By underlining the social relevance of the project, the investigators anticipate that at least 80% of the invited subjects will be interested in participating in this research.
In the first phase, the request for analysis of this project by the Ethics Committee and the Scientific Council of the University of Évora was made. After approval, the entities were contacted to present the project and start contact with the participants. Then, each participant (or their legal tutor) gave informed consent, where they were aware of the confidentiality of the data collected throughout the study and that they would not be disclosed, being only used for academic purposes.
Subjects were invited to participate in three organizations: Espírito Santo Hospital of Évora (HESE) and two Residential Centers for the Elderly. Two types of participants were recruited in these organizations. At HESE, participants with a diagnosis of dementia (validated by the medical team of the Neurology Service) and some of their healthy family members (without a diagnosis). At the Residential Centre for the Elderly, participants who did not have any medical diagnosis record were subject to a neuropsychological evaluation (lasting approximately 60 minutes) to differentiate the group of participants with and without dementia (and not to define which type of dementia). All participants will take a handwriting assessment (lasting approximately 60 minutes).
The data will be analyzed using the Statistical Package for the Social Sciences [SPSS] to conduct a cross-sectional study.
For the neuropsychological assessment, the following instruments will be used:
- Semi-structured interview of neuropsychological anamnesis. This interview was conducted directly with the individual, and will be divided into nine topics: i) personal data, ii) reason for the request, iii) clinical history, iv) school and professional background, v) complaints, vi) impact of brain injury, vii) other information, viii) the rationale of the neuropsychological assessment and ix) inventory on the anamnesis as the first occasion of evaluation (via direct observation method);
- The Geriatric Depression Scale (GDS) is a scale specifically developed for use in the elderly population, which combines administration and an easy-to-use response format. It consists of 30 items that have two possible answers (Yes; No) with two domains: cognitive and affective. The total result varies between 0 and 30 points: 0-10 points (absence of depressive symptoms),11-20 points (mild depressive symptoms) or 21-30 points (severe depressive symptoms);
- -The Mini-Mental State Examination (MMSE) is one of the most widely used instruments in screening cognitive deficits. The cut-off points are 22 for literacy from 0 to 2 years, 24 for literacy from 3 to 6 years, and 27 for literacy equal to or greater than 7 years.
- The Mattis Dementia Rating Scale (DRS-2) is a validated neuropsychological battery for assessing cognition in general, including attention, initiative/perseverance, visuospatial construction, conceptualization, and memory. The cut-off point used is the tenth percentile of normative data for the Portuguese population of age and educational level;
- Clock Design Test is a neuropsychological test, often used in dementia screening.
The handwriting assessment will be carried out by a psychomotor therapist with extensive experience. The instruments will be:
- Beery Buktenica Visual-Motor Integration Development Test - 6 (VMI-6), to be the visual-motor integration, the Portuguese translation and adaptation of the This instrument are composed of three distinct tests - Visuomotor Integration Development Test, Visual Perception Development Test and Motor Coordination Development Test - evaluates visual-motor integration, visuo-perceptual skills and motor coordination, respectively.
- Adult Writing Assessment Battery (HAB). To assess pen control, writing speed, and readability in adults, a). This battery of tests includes different subtests to assess motor and writing skills used in everyday life. Each sub-test is assessed by a specific algorithm, which determines the percentage of letters and numbers that the participant can write legibly. The final evaluation is carried out on a quotation sheet. The HAB will be carried out on a Wacom digitizing platform and the data extraction will be done through the MovAlyzeR software.
- NeuroScript MovAlyzeR software (version 6.1) will be used to analyze the performance of older adults on VMI in relation to spatial, temporal, and kinematic variables of writing.
- EPOC X is a noninvasive wireless electrophysiology procedure that will be used to assess brain activity during the handwriting task (through the HAB).
- The Movsense application enables the use of portable sensors, which can be affixed to the individual's skin or clothing and collect various biomechanical data associated with arm movement.
The data will be collected individually, directly with the individual, in the classroom using a table and a chair to perform the tasks in two sessions: one for neuropsychological assessment and the other for motor assessment. This data collection will take place after the completion of the Informed Consent.
Stroke, vertical/horizontal start position, vertical/horizontal size, slant, reaction time, duration, and pen pressure will be aggregated to obtain the handwriting cinematics.
The brain activity will be measured by the calculation of the spectral density mean from theta, alpha-1and beta bands.
Handwriting legibility will be given by the total score from HAB and the visuomotor will be reported by total and partial score from the VMI-6.
- Conditions
- Dementia
- Keywords
- Prevention, Electroencephalography, Handwriting, Movement
- Medical subject headings
- Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: subjects with dementia Group 2: subjects without dementia o Group/Cohort Description [*] | Group 1: subjects over the age of 50, with a diagnosis of dementia according to DSM-5 criteria and proven by neuropsychological assessment. Group 2: subjects over the age of 50, with no cognitive impairment on the neuropsychological assessment and with no previous neurological and/or psychiatric history or other illnesses that could interfere with the collection of writing data. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stroke
A stroke is a series of lines or curves written in a single letter, i.e., the path traced by the pen on the paper. Traces are analyzed movements that unite a movement pattern. A movement pattern can be segmented using 2 segmentation methods: zero crossings of the velocity profile after the velocity peak or the minimum velocity after the velocity peak. This measure is obtained through the software Movalyzer, during the handwriting tasks.
Measured: Baseline
Vertical/horizontal start position
Initial vertical/horizontal position relative to the lower limit of the digitizer area (in cm).
Measured: Baseline
Vertical/horizontal size
Vertical vector difference between the start and end of a stroke (in cm).
Measured: Baseline
Slant
Segment slope, which is estimated by the orientation of the line by minimizing/reducing the sum of the squares of the perpendicular distances of all pixels to the line through the gravity point (in radians).
Measured: Baseline
Reaction time
Is the time from the start of the recording to the start of the trace (in sec).
Measured: Baseline
Duration
Time interval between the first and last samples in a stroke/segment (in sec).
Measured: Baseline
Pen pressure
Average pen pressure values along a stroke (N/m2).
Measured: Baseline
Brain activity
Spectral density mean from the frequency of the three bands (theta, alpha, beta)
Measured: Baseline
Secondary outcomes (3)
Handwriting legibility
Handwriting legibility will be obtained through the Handwriting Assessment Battery's (HAB) partial score. There is no maximum or minimum. The higher the legibility percentage, the higher the number of legible letters and numbers.
Measured: Baseline
Handwriting speed
Handwriting speed will be obtained through the Handwriting Assessment Battery's (HAB) partial score. There is no maximum or minimum. The shorter the handwriting time, the better the handwriting speed.
Measured: Baseline
Visuomotor integration
- Visuomotor integration will be obtained through the total score of the test Beery Buktenica - 6 (VMI-6). There is no maximum or minimum score. The higher the raw score, the higher the percentile, which corresponds to better visuomotor integration.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2024
- Study start2 Dec 2023
- Primary completion30 Jul 2024
- Study completion30 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Évora
- Sponsor type
- University, hospital or other
- Collaborators
- NOVA Medical School, Faculdade de Motricidade Humana, University of Lisbon
- Responsible party
- Principal investigator, Ana Rita Matias, University of Évora
- Investigators
- Ana Matias, PhD, Principal investigator, University of Évora
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06483438
- Sponsor's protocol ID
- CHRC2022Handwriting&Dementia
- Acronym
- HAD
- Status last verified
- Jun 2024
- First submitted
- 7 Jun 2024
- Last updated
- 9 Aug 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Yes: There is a plan to make IPD and related data dictionaries available. All IPD that underlie results in a publication will be shared. Specifically, data from variables mentioned previously, age, gender, and group label.
Publications
Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct;42(14):1203-12. doi: 10.1016/j.jpsychires.2008.01.006. Epub 2008 Feb 15.
PubMed 18280503Stergiou N, Harbourne R, Cavanaugh J. Optimal movement variability: a new theoretical perspective for neurologic physical therapy. J Neurol Phys Ther. 2006 Sep;30(3):120-9. doi: 10.1097/01.npt.0000281949.48193.d9.
PubMed 17029655Palmis S, Danna J, Velay JL, Longcamp M. Motor control of handwriting in the developing brain: A review. Cogn Neuropsychol. 2017 May-Jun;34(3-4):187-204. doi: 10.1080/02643294.2017.1367654. Epub 2017 Sep 11.
PubMed 28891745Morgado J, Rocha CS, Maruta C, Guerreiro M, Martins IP. Cut-off scores in MMSE: a moving target? Eur J Neurol. 2010 May;17(5):692-5. doi: 10.1111/j.1468-1331.2009.02907.x. Epub 2009 Dec 29.
PubMed 20050900Harbourne RT, Stergiou N. Movement variability and the use of nonlinear tools: principles to guide physical therapist practice. Phys Ther. 2009 Mar;89(3):267-82. doi: 10.2522/ptj.20080130. Epub 2009 Jan 23.
PubMed 19168711Garre-Olmo J, Faundez-Zanuy M, Lopez-de-Ipina K, Calvo-Perxas L, Turro-Garriga O. Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls. Curr Alzheimer Res. 2017;14(9):960-968. doi: 10.2174/1567205014666170309120708.
PubMed 28290244Engel-Yeger B, Hus S, Rosenblum S. Age effects on sensory-processing abilities and their impact on handwriting. Can J Occup Ther. 2012 Dec;79(5):264-74. doi: 10.2182/CJOT.2012.79.5.2.
PubMed 23539771Dixon RA, Kurzman D, Friesen IC. Handwriting performance in younger and older adults: age, familiarity, and practice effects. Psychol Aging. 1993 Sep;8(3):360-70. doi: 10.1037//0882-7974.8.3.360.
PubMed 8216956Galrinho J, Fernandes O, Silva AR, Goncalves-Montera MA, Matias AR. Handwriting speed and pen motor control in older adults with and without cognitive impairment. Front Hum Neurosci. 2026 May 20;20:1820193. doi: 10.3389/fnhum.2026.1820193. eCollection 2026.
PubMed 42245916
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Handwriting as an Objective Tool to Support the Identification of People With Alzheimer's Disease: Suitability of an Assessment Protocol
- ClinicalTrials.gov ID
- NCT06483438
- Acronym / sponsor ID
- HAD / CHRC2022Handwriting&Dementia
- Conditions
- Dementia
- Keywords
- Prevention, Electroencephalography, Handwriting, Movement
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of ÉvoraUniversity, hospital or other
- Collaborators
- NOVA Medical School, Faculdade de Motricidade Humana, University of Lisbon
- Study start
- 2 Dec 2023 (actual)
- Primary completion
- 30 Jul 2024 (actual)
- Study completion
- 30 Jul 2024 (actual)
- First posted
- 3 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alzheimer's disease (AD) is the most common of dementia, and has associated cognitive and motor disorders, with consequences on daily activities, including handwriting.
Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations. Changes in this skill are present at different stages of the clinical course of Alzheimer's Disease. The sensorimotor deterioration is observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles) and brain activity rhythms.
Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations, and changes in this skill are present at different stages of the clinical course of dementia. From a theoretical perspective, because sensorimotor deterioration observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles).
Due to the large number of brain areas related to handwriting performance, brain electrical activity analysis can be an early indicator of brain dysfunction. Although there is a lack of validation across healthy and non-healthy populations Electroencephalogram (EEG) measures have the potential for evaluating cognitive performance.
This research aims to analyze the suitability of the handwriting assessment protocol, which can contribute to a more in-depth knowledge of this subject and potentially support early identification and treatment.
Detailed description
The minimum sample size for this pilot study is 75 participants, which is the minimum sample size calculated by G*power (90% power, significance level 0.05) to perform the planned between-group comparisons (ANOVA), correlations (Pearson), and nonlinear analyses. Participants who agree to participate in this study will be asked to provide demographic information, such as age, Portuguese as a native language, education level, motor/physical problems, and medical problems. By underlining the social relevance of the project, the investigators anticipate that at least 80% of the invited subjects will be interested in participating in this research.
In the first phase, the request for analysis of this project by the Ethics Committee and the Scientific Council of the University of Évora was made. After approval, the entities were contacted to present the project and start contact with the participants. Then, each participant (or their legal tutor) gave informed consent, where they were aware of the confidentiality of the data collected throughout the study and that they would not be disclosed, being only used for academic purposes.
Subjects were invited to participate in three organizations: Espírito Santo Hospital of Évora (HESE) and two Residential Centers for the Elderly. Two types of participants were recruited in these organizations. At HESE, participants with a diagnosis of dementia (validated by the medical team of the Neurology Service) and some of their healthy family members (without a diagnosis). At the Residential Centre for the Elderly, participants who did not have any medical diagnosis record were subject to a neuropsychological evaluation (lasting approximately 60 minutes) to differentiate the group of participants with and without dementia (and not to define which type of dementia). All participants will take a handwriting assessment (lasting approximately 60 minutes).
The data will be analyzed using the Statistical Package for the Social Sciences [SPSS] to conduct a cross-sectional study.
For the neuropsychological assessment, the following instruments will be used:
- Semi-structured interview of neuropsychological anamnesis. This interview was conducted directly with the individual, and will be divided into nine topics: i) personal data, ii) reason for the request, iii) clinical history, iv) school and professional background, v) complaints, vi) impact of brain injury, vii) other information, viii) the rationale of the neuropsychological assessment and ix) inventory on the anamnesis as the first occasion of evaluation (via direct observation method);
- The Geriatric Depression Scale (GDS) is a scale specifically developed for use in the elderly population, which combines administration and an easy-to-use response format. It consists of 30 items that have two possible answers (Yes; No) with two domains: cognitive and affective. The total result varies between 0 and 30 points: 0-10 points (absence of depressive symptoms),11-20 points (mild depressive symptoms) or 21-30 points (severe depressive symptoms);
- -The Mini-Mental State Examination (MMSE) is one of the most widely used instruments in screening cognitive deficits. The cut-off points are 22 for literacy from 0 to 2 years, 24 for literacy from 3 to 6 years, and 27 for literacy equal to or greater than 7 years.
- The Mattis Dementia Rating Scale (DRS-2) is a validated neuropsychological battery for assessing cognition in general, including attention, initiative/perseverance, visuospatial construction, conceptualization, and memory. The cut-off point used is the tenth percentile of normative data for the Portuguese population of age and educational level;
- Clock Design Test is a neuropsychological test, often used in dementia screening.
The handwriting assessment will be carried out by a psychomotor therapist with extensive experience. The instruments will be:
- Beery Buktenica Visual-Motor Integration Development Test - 6 (VMI-6), to be the visual-motor integration, the Portuguese translation and adaptation of the This instrument are composed of three distinct tests - Visuomotor Integration Development Test, Visual Perception Development Test and Motor Coordination Development Test - evaluates visual-motor integration, visuo-perceptual skills and motor coordination, respectively.
- Adult Writing Assessment Battery (HAB). To assess pen control, writing speed, and readability in adults, a). This battery of tests includes different subtests to assess motor and writing skills used in everyday life. Each sub-test is assessed by a specific algorithm, which determines the percentage of letters and numbers that the participant can write legibly. The final evaluation is carried out on a quotation sheet. The HAB will be carried out on a Wacom digitizing platform and the data extraction will be done through the MovAlyzeR software.
- NeuroScript MovAlyzeR software (version 6.1) will be used to analyze the performance of older adults on VMI in relation to spatial, temporal, and kinematic variables of writing.
- EPOC X is a noninvasive wireless electrophysiology procedure that will be used to assess brain activity during the handwriting task (through the HAB).
- The Movsense application enables the use of portable sensors, which can be affixed to the individual's skin or clothing and collect various biomechanical data associated with arm movement.
The data will be collected individually, directly with the individual, in the classroom using a table and a chair to perform the tasks in two sessions: one for neuropsychological assessment and the other for motor assessment. This data collection will take place after the completion of the Informed Consent.
Stroke, vertical/horizontal start position, vertical/horizontal size, slant, reaction time, duration, and pen pressure will be aggregated to obtain the handwriting cinematics.
The brain activity will be measured by the calculation of the spectral density mean from theta, alpha-1and beta bands.
Handwriting legibility will be given by the total score from HAB and the visuomotor will be reported by total and partial score from the VMI-6.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1: subjects with dementia Group 2: subjects without dementia o Group/Cohort Description [*] | – | –Group 1: subjects over the age of 50, with a diagnosis of dementia according to DSM-5 criteria and proven by neuropsychological assessment. Group 2: subjects over the age of 50, with no cognitive impairment on the neuropsychological assessment and with no previous neurological and/or psychiatric history or other illnesses that could interfere with the collection of writing data. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be recruited from Municipal and Community Associations, Senior Universities and Residential Centre for the Elderly
Key inclusion criteria (5 listed)
- Over 50 years of age
- The inclusion criteria for the dementia group are as follows: patients diagnosed with dementia according to the DSM-5 criteria and cognitive impairment proven in the neuropsychological assessment
- Portuguese native language
- Over 50 years of age
- At least three years of schooling
Key exclusion criteria (2 listed)
- Previous neurological history (e.g. stroke, traumatic brain injury, multiple sclerosis, among others), psychiatric history or other incapacitating illnesses that could interfere with the collection of writing data. (NOTE that neurological disease is accepted in the dementia group, but co-morbidity of previous and actual neurological diseases will be excluded) Cognitively normal group
- Presence of neurological history (e.g., stroke, traumatic brain injury, multiple sclerosis, among others), psychiatric history, or other incapacitating illnesses that could interfere with the collection of writing data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Stroke
Time frame: Baseline
A stroke is a series of lines or curves written in a single letter, i.e., the path traced by the pen on the paper. Traces are analyzed movements that unite a movement pattern. A movement pattern can be segmented using 2 segmentation methods: zero crossings of the velocity profile after the velocity peak or the minimum velocity after the velocity peak. This measure is obtained through the software Movalyzer, during the handwriting tasks.
Vertical/horizontal start position
Time frame: Baseline
Initial vertical/horizontal position relative to the lower limit of the digitizer area (in cm).
Vertical/horizontal size
Time frame: Baseline
Vertical vector difference between the start and end of a stroke (in cm).
Slant
Time frame: Baseline
Segment slope, which is estimated by the orientation of the line by minimizing/reducing the sum of the squares of the perpendicular distances of all pixels to the line through the gravity point (in radians).
Reaction time
Time frame: Baseline
Is the time from the start of the recording to the start of the trace (in sec).
Duration
Time frame: Baseline
Time interval between the first and last samples in a stroke/segment (in sec).
Pen pressure
Time frame: Baseline
Average pen pressure values along a stroke (N/m2).
Brain activity
Time frame: Baseline
Spectral density mean from the frequency of the three bands (theta, alpha, beta)
3 secondary outcomes
Handwriting legibility
Time frame: Baseline
Handwriting speed
Time frame: Baseline
Visuomotor integration
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2024.
- Background: PubMed 18280503Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct;42(14):1203-12. doi: 10.1016/j.jpsychires.2008.01.006. Epub 2008 Feb 15.
- Background: PubMed 17029655Stergiou N, Harbourne R, Cavanaugh J. Optimal movement variability: a new theoretical perspective for neurologic physical therapy. J Neurol Phys Ther. 2006 Sep;30(3):120-9. doi: 10.1097/01.npt.0000281949.48193.d9.
- Background: PubMed 28891745Palmis S, Danna J, Velay JL, Longcamp M. Motor control of handwriting in the developing brain: A review. Cogn Neuropsychol. 2017 May-Jun;34(3-4):187-204. doi: 10.1080/02643294.2017.1367654. Epub 2017 Sep 11.
- Background: PubMed 20050900Morgado J, Rocha CS, Maruta C, Guerreiro M, Martins IP. Cut-off scores in MMSE: a moving target? Eur J Neurol. 2010 May;17(5):692-5. doi: 10.1111/j.1468-1331.2009.02907.x. Epub 2009 Dec 29.
- Background: PubMed 19168711Harbourne RT, Stergiou N. Movement variability and the use of nonlinear tools: principles to guide physical therapist practice. Phys Ther. 2009 Mar;89(3):267-82. doi: 10.2522/ptj.20080130. Epub 2009 Jan 23.
- Background: PubMed 28290244Garre-Olmo J, Faundez-Zanuy M, Lopez-de-Ipina K, Calvo-Perxas L, Turro-Garriga O. Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls. Curr Alzheimer Res. 2017;14(9):960-968. doi: 10.2174/1567205014666170309120708.
- Background: PubMed 23539771Engel-Yeger B, Hus S, Rosenblum S. Age effects on sensory-processing abilities and their impact on handwriting. Can J Occup Ther. 2012 Dec;79(5):264-74. doi: 10.2182/CJOT.2012.79.5.2.
- Background: PubMed 8216956Dixon RA, Kurzman D, Friesen IC. Handwriting performance in younger and older adults: age, familiarity, and practice effects. Psychol Aging. 1993 Sep;8(3):360-70. doi: 10.1037//0882-7974.8.3.360.
- Derived from this study: PubMed 42245916Galrinho J, Fernandes O, Silva AR, Goncalves-Montera MA, Matias AR. Handwriting speed and pen motor control in older adults with and without cognitive impairment. Front Hum Neurosci. 2026 May 20;20:1820193. doi: 10.3389/fnhum.2026.1820193. eCollection 2026.
- Neuroscript softwareLink provided by the sponsor.
- MovesenseLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Yes: There is a plan to make IPD and related data dictionaries available. All IPD that underlie results in a publication will be shared. Specifically, data from variables mentioned previously, age, gender, and group label.
Related trials for Dementia
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Active, not recruiting
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Dementia, Cognitive Impairment
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Amnesia, Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ana Matias, PhD principal investigator
University of Évora
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dementia, run by University of Évora at 3 sites in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stroke (time frame: Baseline). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06483438, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2024.